Dissecting the Evidence Interpreting Recent Clinical Trial Data for Radiopharmaceutical-Based Combinations in Metastatic Castration-Resistant Prostate Cancer CME Wednesday, February 18, 2026 | 1:00 pm - 1:30 pm ET Virtual

https://events.medscapelive.org/website/92806/?utm_source=mrk&utm_campaign=451100.10a453185.10a_oncologysolidtumoronco_webinarlive_bayerglobal_eduvirtual&utm_medium=em&utm_content=int In this interactive webinar, leading prostate cancer specialists will examine current guidelines and seminal clinical trial data on radiopharmaceutical-based treatments in metastatic castration-resistant prostate cancer (mCRPC) and discuss how these agents can be incorporated into clinical practice. Our expert faculty will provide actionable guidance on such topics as patient selection, sequencing, and safety monitoring with radiopharmaceutical therapies in order to optimize patient outcomes and quality of life. The 30-minute session concludes with live Q&A when participants can pose questions directly to faculty. Therapeutic opportunity is evolving significantly in first line management of mCRPC with the introduction of radiopharmaceutical therapies earlier in the treatment pathway. This expert webinar series has been created to build awareness of the upcoming shifts in practice and enhance clinicians' ability to integrate novel therapies into their practice once available.